The YBM Magnex Files Adrian du Plessis ... - Deep Capture
The YBM Magnex Files Adrian du Plessis ... - Deep Capture
The YBM Magnex Files Adrian du Plessis ... - Deep Capture
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Proposing a corporate name change to US Biogenix, the new President Skillern explained:<br />
?<strong>The</strong> original name reflected the use of cryopreservation in our proposed pregnancy suspension<br />
technology, but unfortunately the social, ideological and political opponents made it impossible<br />
to deliver that service so we redirected our efforts toward telomere biology and its applications<br />
to aging, cancer and other therapies.?<br />
A cure for cancer may be a goal sufficient for some to achieve, but CYGS saw wider benefits to<br />
be realized from ?optimizing the value of the TeloVector ? in all its manifestations.? This<br />
technology, it was stated, was expected to have application to the shrimp farming in<strong>du</strong>stry and<br />
the company reported it would ?spin off (its) aquaculture division into a separate corporation.?<br />
CYGS director of research Craig Tomlinson, PhD, said, ?We believe we can grow more shrimp,<br />
faster and larger, and pro<strong>du</strong>ce a ?clean? shrimp, free of environmental or viral contaminants.?<br />
Cancer cures and bigger, healthier, shrimp promised by a OTC stock venture trading for dimes<br />
and promoted by an S&M advocate may not raise too many eyebrows in today?s investment<br />
climate, but Cryogenic?s other press release of January 5 1998 did cause some dissonance in<br />
financial chat circles on-line.<br />
CYGS announced that it had agreed to license its TeleVector ? technology to something called<br />
Clinica Lirpa, S.A. of Costa Rica. According to Mike Skillern, ?Clinica Lirpa, S.A. is especially<br />
interested in the gerontology (anti-aging) and oncology (anti-cancer) applications of the<br />
TeloVector.? Such an arrangement with an obscure Central American entity is not that out-ofthe-ordinary<br />
for a typically surreal junior public company.<br />
(I recall investigating one Canadian public company, Technigen Corp., that claimed to be selling<br />
over CDN $100 million worth of computerized golf driving ranges to Corporacion Relacio, S.A. -<br />
purportedly a Swiss company. Even though it was documented that Relacio, S.A. was, in fact, a<br />
Panamanian-registered shell whose signing representative in Canada was an ex-convict stock<br />
swindler who?d been banned for life from the Vancouver Stock Exchange, VSE officials were<br />
satisfied. Coincidentally, a founding Technigen shareholder, and its subsequent head of<br />
Investor Relations, Michael Schmidt, was one of the founding directors of Pratecs/<strong>YBM</strong>.)<br />
What drew the disdain of several internet stock-watchers was the company?s declaration: ?As a<br />
condition of the license agreement, Clinica Lirpa has agreed to ?preferential access? for anyone<br />
owning 5,000 or more shares of (Cryogenic Solutions) common stock as of March 1, 1998.<br />
?Essentially, Clinica Lirpa will confirm reservations to qualified indivi<strong>du</strong>als with at least 5,000<br />
shares registered in their name,? said Skillern. ?Everyone else will be served on a space<br />
available basis. This preferential service access will be for all services offered by Clinica Lirpa,<br />
not just services developed from our TeleVector ? ?.?<br />
When Silicon Investor posters reacted by calling this news ?spooky and unethical?,<br />
?PREJUDICIAL? and ?completely bizarro? one of a tag-team of on-line boosters, Barry R.,<br />
jumped to the defense of CYGS: ?Overall I think it?s a great idea to make patients part owners